// App-Quantinova.ai

BSH2020‐OR‐018 : Four‐year follow‐up of the phase 3 POLLUX study of daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in relapsed or refractory multiple myeloma

Researchers

Presenter

  • G. Cook

Principal Investigators

  • S. Z. Usmani

  • J. San-Miguel

  • N. J. Bahlis

  • D. White

  • L. Benboubker

  • M. Leiba

  • P. J. Ho

  • K. Kim

  • N. Takezako

  • P. Moreau

  • M. Krevvata

  • H. Pei

  • J. Ukropec

  • T. Renaud

  • S. Trivedi

  • R. Kobos

  • M. A. Dimopoulos

Medical Centers

  • St James's Institute of Oncology, Leeds Teaching Hospitals NHS Trust and University of Leeds, Leeds, United Kingdom

  • Winship Cancer Institute of Emory University, Atlanta, GA

  • Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC

  • Clinica Universidad de Navarra-CIMA, IDISNA, CIBERONC, Pamplona, Spain

  • Charbonneau Cancer Institute at the University of Calgary, Calgary, AB, Canada

  • Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada

  • Service dHematologie et Therapie Cellulaire, Hopital Bretonneau, Centre Hospitalier Regional Universitaire (CHRU), Tours, France

  • Assuta University Hospital, Faculty of Health Science, Ben-Gurion University of the Negev, Beersheba, Israel

  • Institute of Academic Surgery, Royal Prince Alfred Hospital, Camperdown, Australia

  • Department of Critical Care Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of,

  • Department of Hematology, National Hospital Organization Disaster Medical Center of Japan, Tachikawa, Japan

  • Hematology, University Hospital, Nantes, France

  • Janssen Research and Development, LLC, Spring House, PA

  • Janssen Research and Development, Titusville, NJ

  • Janssen Global Medical Affairs, Horsham, PA

  • Janssen Research & Development, LLC, Raritan, NJ

  • National and Kapodistrian University of Athens, Athens, Greece

Locations

  • United Kingdom

  • United States

  • Spain

  • Canada

  • France

  • Israel

  • Australia

  • Japan

  • Greece

  • Republic of South Korea

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Oncology (ONC)

Disease

  • Multiple Myeloma

  • Thrombocytopenia

  • Neutropenia

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Lenalidomide

  • daratumumab Intravenous

  • Sparsentan

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved